|
*DISCLAIMER*: Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, Frankly and this Station make no warranties or representations in connection therewith.
|
Medicine & Pharmaceuticals News Releases via PRNewswireMore>>
Concordia International Corp. Takes Next Step to Realign Its Capital Structure By Commencing Proceedings Under the Canada Business Corporations Act
Concordia International Corp. Takes Next Step to Realign Its Capital Structure By Commencing Proceedings Under the Canada Business Corporations Act
Concordia is seeking to reduce its existing secured and unsecured debt obligations by more than $2 billion, while significantly reducing its annual interest expense (the "Proposed Recapitalization Transaction") Canada...More \232aConcordia is seeking to reduce its existing secured and unsecured debt obligations by more than $2 billion, while significantly reducing its annual interest expense (the "Proposed Recapitalization Transaction") Canada...More \232aGlobal Vascular Imaging Market - Analysis, Technologies & Forecasts to 2021
Global Vascular Imaging Market - Analysis, Technologies & Forecasts to 2021
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, October 20, 2017 /PRNewswire/ -- The "Global Vascular Imaging Market 2017-2021" report has been added to Research and Markets' offering. The global vascula...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, October 20, 2017 /PRNewswire/ -- The "Global Vascular Imaging Market 2017-2021" report has been added to Research and Markets' offering. The global vascula...More \232aGlobal Biomarkers Market Forecast 2017-2027
Global Biomarkers Market Forecast 2017-2027
Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases The global biomarkers market is expected to grow at a CAGR of...More \232aBiomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases The global biomarkers market is expected to grow at a CAGR of...More \232aPursuing Novel Pathways in Immunology: Merck KGaA, Darmstadt, Germany Presents New Clinical Data at 2017 ACR/ARHP Annual Meeting
Pursuing Novel Pathways in Immunology: Merck KGaA, Darmstadt, Germany Presents New Clinical Data at 2017 ACR/ARHP Annual Meeting
Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced 11 abstracts are scheduled for presentation in oral and...More \232aMerck KGaA, Darmstadt, Germany, a leading science and technology company which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced 11 abstracts are scheduled for presentation in oral and...More \232aDURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48...More \232aDURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement over the first 48...More \232aGlobal $25 Billion Biosensors Market, 2022
Global $25 Billion Biosensors Market, 2022
The "Biosensors - A Global Market Overview" report has been added to Research and Markets' offering. Global Biosensors market is expected to record a robust CAGR of about 9% during the 2017-2022 analysis period and...More \232aThe "Biosensors - A Global Market Overview" report has been added to Research and Markets' offering. Global Biosensors market is expected to record a robust CAGR of about 9% during the 2017-2022 analysis period and...More \232aAsia Pacific Nutraceuticals Market Outlook Report 2017-2021
Asia Pacific Nutraceuticals Market Outlook Report 2017-2021
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, October 19, 2017 /PRNewswire/ -- The "Asia Pacific Nutraceuticals Market Outlook 2021 - Presence of Huge Customer Base coupled with Rising Disposable Income in ...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, October 19, 2017 /PRNewswire/ -- The "Asia Pacific Nutraceuticals Market Outlook 2021 - Presence of Huge Customer Base coupled with Rising Disposable Income in ...More \232aCytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival
CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the...More \232aCytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the...More \232aGlobal Cannabis Operations and Production Booming With Opportunity and Forecasted Growth Potential
Global Cannabis Operations and Production Booming With Opportunity and Forecasted Growth Potential
In a report issued this year by Ameri Research Inc., they estimate Global Cannabis Industry was valued at $14.3 Billion in 2016 and is forecast to grow at a CAGR of 21.1% between 2017 and 2024, culminating in 2024 Global...More \232aIn a report issued this year by Ameri Research Inc., they estimate Global Cannabis Industry was valued at $14.3 Billion in 2016 and is forecast to grow at a CAGR of 21.1% between 2017 and 2024, culminating in 2024 Global...More \232aCognitio Unveils Insider360™ Threat Risk Mitigation Services, Enabling Clients to Assess and Reduce Risk of Critical Compromise
Cognitio Unveils Insider360™ Threat Risk Mitigation Services, Enabling Clients to Assess and Reduce Risk of Critical Compromise
Cognitio, a strategic consulting and engineering firm led by a team of former senior technology executives from the U.S. Intelligence Community and financial sector, has announced a set of offerings based on their insider...More \232aCognitio, a strategic consulting and engineering firm led by a team of former senior technology executives from the U.S. Intelligence Community and financial sector, has announced a set of offerings based on their insider...More \232aKent Imaging Revolutionizes Perfusion Imaging with Their FDA Cleared KD203
Kent Imaging Revolutionizes Perfusion Imaging with Their FDA Cleared KD203
CALGARY, Oct. 19, 2017 /PRNewswire/ - Kent Imaging, a leading provider of near infrared imaging solutions, announced today that the U.S. Food and Drug Administration (FDA) has cleared their multispectral Medical Imaging...More \232aCALGARY, Oct. 19, 2017 /PRNewswire/ - Kent Imaging, a leading provider of near infrared imaging solutions, announced today that the U.S. Food and Drug Administration (FDA) has cleared their multispectral Medical Imaging...More \232aPrometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim™)
Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim™)
Prometic plans to file its NDS with Health Canada in the fourth quarter of 2017 LAVAL, QC, Oct. 19, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Health Canada...More \232aPrometic plans to file its NDS with Health Canada in the fourth quarter of 2017 LAVAL, QC, Oct. 19, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Health Canada...More \232aAs Medical Device Market is Forecast at $450 Billion, Imua Services Equips the Next Generation of Startups with New Online Training
As Medical Device Market is Forecast at $450 Billion, Imua Services Equips the Next Generation of Startups with New Online Training
According to The International Trade Association, the global medical device, technology and equipment market is growing from $360 B to $450 B in 2018. While there's tremendous opportunity for startups and entrepreneurs...More \232aAccording to The International Trade Association, the global medical device, technology and equipment market is growing from $360 B to $450 B in 2018. While there's tremendous opportunity for startups and entrepreneurs...More \232aAllergan Issues Investor FAQ on Federal District Court RESTASIS® Patent Decision
Allergan Issues Investor FAQ on Federal District Court RESTASIS® Patent Decision
Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today issued an FAQ document responding to investor questions following the U.S. District Court for the Eastern District of Texas trial decision on the...More \232aAllergan plc (NYSE:AGN), a leading global biopharmaceutical company, today issued an FAQ document responding to investor questions following the U.S. District Court for the Eastern District of Texas trial decision on the...More \232aDigital Pharmacist Appoints Michael Pierce as Vice President of Sales
Digital Pharmacist Appoints Michael Pierce as Vice President of Sales
Digital Pharmacist Inc. (www.digitalpharmacist.com), a rapidly growing digital health company that powers the digital, communication and adherence solutions for 6,000 pharmacies, national pharmacy wholesalers, and hospital...More \232aDigital Pharmacist Inc. (www.digitalpharmacist.com), a rapidly growing digital health company that powers the digital, communication and adherence solutions for 6,000 pharmacies, national pharmacy wholesalers, and hospital...More \232aArmy Veteran Provides Peer Support to Female Warriors at Mental Health Workshop
Army Veteran Provides Peer Support to Female Warriors at Mental Health Workshop
At a recent Wounded Warrior Project® (WWP) mental health workshop in Tampa, Florida, a group of women veterans received critical peer support from a fellow female warrior who experienced similar hurdles after military...More \232aAt a recent Wounded Warrior Project® (WWP) mental health workshop in Tampa, Florida, a group of women veterans received critical peer support from a fellow female warrior who experienced similar hurdles after military...More \232aInsulin in People Living with Type 2 Diabetes: Initiation and Dosage
Insulin in People Living with Type 2 Diabetes: Initiation and Dosage
Favourable results from a scientific study conducted by Canadian investigators on the dosage adjustment of Toujeo®More \232aFavourable results from a scientific study conducted by Canadian investigators on the dosage adjustment of Toujeo®More \232aDicom Systems Enterprise Imaging Unifier Earns RSNA Image Share Validation
Dicom Systems Enterprise Imaging Unifier Earns RSNA Image Share Validation
Dicom Systems, Inc. (www.dcmsys.com), a Silicon Valley-based healthcare IT company specializing in Enterprise Imaging interoperability, successfully completed the RSNA Image Share Validation program that extensively tests...More \232aDicom Systems, Inc. (www.dcmsys.com), a Silicon Valley-based healthcare IT company specializing in Enterprise Imaging interoperability, successfully completed the RSNA Image Share Validation program that extensively tests...More \232aTherapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea
Therapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea
Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, signed an agreement with Assuta...More \232aTherapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, signed an agreement with Assuta...More \232aFluoroscopy and Mobile C-Arms Markets 2016-2024 - Fluoroscopy Dominates Value-wise, Mobile C-Arms to Witness Faster Growth
Fluoroscopy and Mobile C-Arms Markets 2016-2024 - Fluoroscopy Dominates Value-wise, Mobile C-Arms to Witness Faster Growth
The "Fluoroscopy and Mobile C-Arms - Global Strategic Business Report" report has been added to Research and Markets' offering. This report analyzes the worldwide markets for Fluoroscopy and Mobile C-Arms in US$...More \232aThe "Fluoroscopy and Mobile C-Arms - Global Strategic Business Report" report has been added to Research and Markets' offering. This report analyzes the worldwide markets for Fluoroscopy and Mobile C-Arms in US$...More \232aMerck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017
Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Merck - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad - Continued innovation with Rebif includes analysis of NEDA a...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Merck - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad - Continued innovation with Rebif includes analysis of NEDA a...More \232aU.S. patent granted for Benitec hepatitis B program
U.S. patent granted for Benitec hepatitis B program
Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that a new patent relating to the Company's hepatitis B program has been issued in the United States. Titled "HBV Treatment" and...More \232aBenitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that a new patent relating to the Company's hepatitis B program has been issued in the United States. Titled "HBV Treatment" and...More \232aAbbott Reports Third-Quarter 2017 Results
Abbott Reports Third-Quarter 2017 Results
Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2017.More \232aAbbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2017.More \232aNovartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Novartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with chronic/persistent (enrolling patients that were 6 or more months from diagnosis) immune...More \232aNovartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with chronic/persistent (enrolling patients that were 6 or more months from diagnosis) immune...More \232aMedicenna Announces Trading on the OTCQX Best Market in the United States
Medicenna Announces Trading on the OTCQX Best Market in the United States
TORONTO and HOUSTON, TX, Oct. 18, 2017 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that the Company...More \232aTORONTO and HOUSTON, TX, Oct. 18, 2017 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that the Company...More \232aSectra's Digital Pathology Solution Selected for External Quality Assurance Program
Sectra's Digital Pathology Solution Selected for External Quality Assurance Program
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) signs digital pathology contract with the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP). Sectra's...More \232aInternational medical imaging IT and cybersecurity company Sectra (STO: SECT B) signs digital pathology contract with the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP). Sectra's...More \232aMeiraGTx Presents Preclinical Data on its Ocular Gene Therapy Studies for the Treatment of Leber's Congenital Amaurosis, Achromatopsia and X-Linked Retinitis Pigmentosa at ESGCT 2017 Congress in Berlin
MeiraGTx Presents Preclinical Data on its Ocular Gene Therapy Studies for the Treatment of Leber's Congenital Amaurosis, Achromatopsia and X-Linked Retinitis Pigmentosa at ESGCT 2017 Congress in Berlin
MeiraGTx, a New York and London based gene therapy company, today announced the presentation of preclinical data from studies in animal models of Leber's congenital amaurosis (LCA2), achromatopsia, and X-linked...More \232aMeiraGTx, a New York and London based gene therapy company, today announced the presentation of preclinical data from studies in animal models of Leber's congenital amaurosis (LCA2), achromatopsia, and X-linked...More \232aMNA Retraction of Oct. 17, 2017 Press Release Regarding Berkshire Medical Center
MNA Retraction of Oct. 17, 2017 Press Release Regarding Berkshire Medical Center
The MNA has retracted a statement made via press release earlier today concerning the status of an unfair labor practice charge filed by Berkshire Medical Center against the MNA, which was made in error.More \232aThe MNA has retracted a statement made via press release earlier today concerning the status of an unfair labor practice charge filed by Berkshire Medical Center against the MNA, which was made in error.More \232aTechnology Innovations for Patient Engagement 2017 - Digital Technologies Transforming Patient Engagement Industry
Technology Innovations for Patient Engagement 2017 - Digital Technologies Transforming Patient Engagement Industry
The "Technology Innovations for Patient Engagement" report has been added to Research and Markets' offering. This research service showcases the different technology innovations in patient engagement and how is it...More \232aThe "Technology Innovations for Patient Engagement" report has been added to Research and Markets' offering. This research service showcases the different technology innovations in patient engagement and how is it...More \232aOne Drop Announces "Revive" Digital Weight Loss And Diabetes Prevention Program
One Drop Announces "Revive" Digital Weight Loss And Diabetes Prevention Program
One Drop today announced the Centers for Disease Control and Prevention (CDC) have awarded Pending Recognition to its newest addition to the One Drop | Experts education platform: Revive. Revive is a 12-month weight loss...More \232aOne Drop today announced the Centers for Disease Control and Prevention (CDC) have awarded Pending Recognition to its newest addition to the One Drop | Experts education platform: Revive. Revive is a 12-month weight loss...More \232aLumenis to Highlight the Positive Impact of its FiberLase™ CO2 Laser Treatment for Ovarian Endometrioma on Ovarian Reserve
Lumenis to Highlight the Positive Impact of its FiberLase™ CO2 Laser Treatment for Ovarian Endometrioma on Ovarian Reserve
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced today that it will share new clinical data on its CO2 laser-based FiberLase™ for...More \232aLumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced today that it will share new clinical data on its CO2 laser-based FiberLase™ for...More \232aStudy Results of ACT-101 in a Model of Inflammatory Bowel Disease (IBD) Presented at the World Congress of Gastroenterology 2017
Study Results of ACT-101 in a Model of Inflammatory Bowel Disease (IBD) Presented at the World Congress of Gastroenterology 2017
Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on therapies for patients with autoimmune diseases and cancer, today announced the results of a study of ACT-101 (recombinant human alpha fetoprotein...More \232aAlpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on therapies for patients with autoimmune diseases and cancer, today announced the results of a study of ACT-101 (recombinant human alpha fetoprotein...More \232aPressure looms for coverage of medical marijuana; B.C. Medical Services Plans premiums reduced
Pressure looms for coverage of medical marijuana; B.C. Medical Services Plans premiums reduced
An in-depth look at these and other subjects are covered in the current issue of the Morneau Shepell News & ViewsMore \232aAn in-depth look at these and other subjects are covered in the current issue of the Morneau Shepell News & ViewsMore \232aGlobal Radiation Oncology Market Research Report 2017
Global Radiation Oncology Market Research Report 2017
The "Global Radiation Oncology Market 2017-2021" report has been added to Research and Markets' offering. The global radiation oncology market to grow at a CAGR of 5.29% during the period 2017-2021. Global Radiation...More \232aThe "Global Radiation Oncology Market 2017-2021" report has been added to Research and Markets' offering. The global radiation oncology market to grow at a CAGR of 5.29% during the period 2017-2021. Global Radiation...More \232aSan Francisco Health Plan is Recognized for Outstanding Performance in Quality Care From The California Department of Health Care Services
San Francisco Health Plan is Recognized for Outstanding Performance in Quality Care From The California Department of Health Care Services
San Francisco Health Plan (SFHP), a community health plan serving over 145,000 San Francisco residents, announced today that it is the recipient of the 2017 Outstanding Performance in Quality Care from the California...More \232aSan Francisco Health Plan (SFHP), a community health plan serving over 145,000 San Francisco residents, announced today that it is the recipient of the 2017 Outstanding Performance in Quality Care from the California...More \232aGlobal Chromatography Syringes Market, 2022 - Increasing Use of Chromatography Techniques in Drug Approval
Global Chromatography Syringes Market, 2022 - Increasing Use of Chromatography Techniques in Drug Approval
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, October 17, 2017 /PRNewswire/ -- The "Chromatography Syringes Market - Global Opportunity Analysis And Industry Forecast (2017-2022)" report has been added to R...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, October 17, 2017 /PRNewswire/ -- The "Chromatography Syringes Market - Global Opportunity Analysis And Industry Forecast (2017-2022)" report has been added to R...More \232aNaturopathic Medicine Supports Breast Cancer Treatment and Prevention
Naturopathic Medicine Supports Breast Cancer Treatment and Prevention
For patients with breast cancer, naturopathic medicine can help optimize tolerance to conventional medical treatments and also provide strategies to reinforce the body's natural defenses and recovery systems. This is...More \232aFor patients with breast cancer, naturopathic medicine can help optimize tolerance to conventional medical treatments and also provide strategies to reinforce the body's natural defenses and recovery systems. This is...More \232aMenlo Therapeutics Expands its Management Team
Menlo Therapeutics Expands its Management Team
Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK-1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) associated with various underlying conditions, and...More \232aMenlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK-1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) associated with various underlying conditions, and...More \232aSimplyVital Health Partners With Toro Risk Consulting Group On Transformational Blockchain Healthcare Technology
SimplyVital Health Partners With Toro Risk Consulting Group On Transformational Blockchain Healthcare Technology
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE SimplyVital Health BLOOMFIELD, Connecticut, October 17, 2017 /PRNewswire/ -- SimplyVital Health (SVH) and Toro Risk Consulting Group, LLC (Toro) have announced an ...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE SimplyVital Health BLOOMFIELD, Connecticut, October 17, 2017 /PRNewswire/ -- SimplyVital Health (SVH) and Toro Risk Consulting Group, LLC (Toro) have announced an ...More \232aiSTAR Medical Completes Enrolment of First-in-human MIGS Trial
iSTAR Medical Completes Enrolment of First-in-human MIGS Trial
iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the completion of enrolment in their first-in-human (FIH) micro-invasive glaucoma...More \232aiSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the completion of enrolment in their first-in-human (FIH) micro-invasive glaucoma...More \232aMedical Grade Silicone Market Worth $596.8 Million by 2025 | CAGR: 6.6%: Grand View Research, Inc.
Medical Grade Silicone Market Worth $596.8 Million by 2025 | CAGR: 6.6%: Grand View Research, Inc.
The global medical grade silicone market is expected to reach USD 596.8 million by 2025, growing at a CAGR of 6.6%, according to a report by Grand View Research, Inc. Rising demand for Medical Grade Silicone owing to its...More \232aThe global medical grade silicone market is expected to reach USD 596.8 million by 2025, growing at a CAGR of 6.6%, according to a report by Grand View Research, Inc. Rising demand for Medical Grade Silicone owing to its...More \232aHenry Schein Medical Announces Exclusive Distribution Agreement With Terason® For Ultrasound Device
Henry Schein Medical Announces Exclusive Distribution Agreement With Terason® For Ultrasound Device
Henry Schein Medical today announced that its Emergency Medical Services (EMS) business has entered an exclusive agreement with Terason® to distribute uSmart® 3200T NexGen, a portable ultrasound device that enables...More \232aHenry Schein Medical today announced that its Emergency Medical Services (EMS) business has entered an exclusive agreement with Terason® to distribute uSmart® 3200T NexGen, a portable ultrasound device that enables...More \232aSierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017
- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer -More \232a- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer -More \232aDarholding Portfolio Company to List on LSE
Darholding Portfolio Company to List on LSE
Darholding is pleased to announce that one of its portfolio companies, Nuformix, will list on the London Stock Exchange via a reverse takeover of Levrett PLC. Darholding was one of the founders, along with other private...More \232aDarholding is pleased to announce that one of its portfolio companies, Nuformix, will list on the London Stock Exchange via a reverse takeover of Levrett PLC. Darholding was one of the founders, along with other private...More \232aTSRI's Benjamin Cravatt Elected to National Academy of Medicine
TSRI's Benjamin Cravatt Elected to National Academy of Medicine
Benjamin Cravatt, professor and co-chair of the Department of Molecular Medicine at The Scripps Research Institute (TSRI), has been elected as a member of the prestigious National Academy of Medicine.More \232aBenjamin Cravatt, professor and co-chair of the Department of Molecular Medicine at The Scripps Research Institute (TSRI), has been elected as a member of the prestigious National Academy of Medicine.More \232aStudy: Only 12 Percent of Medical Students Aware of Key Nutritional Guidelines, Yet 55 Percent Confident in Counseling Patients
Study: Only 12 Percent of Medical Students Aware of Key Nutritional Guidelines, Yet 55 Percent Confident in Counseling Patients
Ohio University researchers found medical students may be more confident than knowledgeable when it comes to nutrition. Of the 257 medical students studied, more than 55 percent were confident they could counsel patients...More \232aOhio University researchers found medical students may be more confident than knowledgeable when it comes to nutrition. Of the 257 medical students studied, more than 55 percent were confident they could counsel patients...More \232aFuture Legal Cannabis Sales Projected to Rise
Future Legal Cannabis Sales Projected to Rise
According to a forecast report by Arcview Market Research, growth in the legal cannabis market will re-accelerate in the beginning of 2018, as adult use (recreational use) sales are expected to ramp up in Canada,...More \232aAccording to a forecast report by Arcview Market Research, growth in the legal cannabis market will re-accelerate in the beginning of 2018, as adult use (recreational use) sales are expected to ramp up in Canada,...More \232aAllergan to Present New Data at the World Congress of Gastroenterology at ACG 2017
Allergan to Present New Data at the World Congress of Gastroenterology at ACG 2017
Allergan plc (NYSE: AGN) today announced that new data from its gastroenterology portfolio will be featured at the World Congress of Gastroenterology (WCOG), American College of Gastroenterology (ACG), from October 13–18,...More \232aAllergan plc (NYSE: AGN) today announced that new data from its gastroenterology portfolio will be featured at the World Congress of Gastroenterology (WCOG), American College of Gastroenterology (ACG), from October 13–18,...More \232aNew Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients
New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients
Takeda Pharmaceutical Company Limited (TSE: 4502), ("Takeda") today announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio® (vedolizumab) in patients with moderately...More \232aTakeda Pharmaceutical Company Limited (TSE: 4502), ("Takeda") today announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio® (vedolizumab) in patients with moderately...More \232aConcordia International Corp. Continues Discussions with Stakeholders; Defers Unsecured Interest Payment Due October 16th as It Works Toward Realignment of its Capital Structure
Concordia International Corp. Continues Discussions with Stakeholders; Defers Unsecured Interest Payment Due October 16th as It Works Toward Realignment of its Capital Structure
Company intends to operate its business as usual while continuing to honour its obligations to employees, suppliers and customers OAKVILLE, ON, Oct. 16, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or...More \232aCompany intends to operate its business as usual while continuing to honour its obligations to employees, suppliers and customers OAKVILLE, ON, Oct. 16, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or...More \232aRule Change Ends Global Prohibition for CBD in Professional Sports
Rule Change Ends Global Prohibition for CBD in Professional Sports
For the first time in the global history of competitive sports, professional athletes around the world can now use CBD infused functional foods and natural health products, free from WADA prohibition.More \232aFor the first time in the global history of competitive sports, professional athletes around the world can now use CBD infused functional foods and natural health products, free from WADA prohibition.More \232aRapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis
Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis
New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA® (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18th World Conference on Lung...More \232aNew subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA® (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18th World Conference on Lung...More \232aIonis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress
Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that new data from the Phase 3 NEURO-TTR study with inotersen in patients with hereditary TTR amyloidosis (hATTR) with...More \232aIonis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that new data from the Phase 3 NEURO-TTR study with inotersen in patients with hereditary TTR amyloidosis (hATTR) with...More \232aJanssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) for the treatment of adolescents (12 years of age or older) with...More \232aJanssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) for the treatment of adolescents (12 years of age or older) with...More \232aOrexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030
Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030
Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that the United States District Court for the District of Delaware issued a ruling in favor of Orexigen in the paragraph IV litigation against Actavis Laboratories...More \232aOrexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that the United States District Court for the District of Delaware issued a ruling in favor of Orexigen in the paragraph IV litigation against Actavis Laboratories...More \232aGSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization from Health Canada
GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization from Health Canada
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Health Canada granted marketing authorization to GlaxoSmithKline's (GSK)...More \232aAgenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Health Canada granted marketing authorization to GlaxoSmithKline's (GSK)...More \232aFocus on psoriasis; Promius Pharma announces 4 posters regarding SERNIVO® (betamethasone dipropionate) Spray, 0.05% at Fall Clinical Dermatology Conference®
Focus on psoriasis; Promius Pharma announces 4 posters regarding SERNIVO® (betamethasone dipropionate) Spray, 0.05% at Fall Clinical Dermatology Conference®
Promius Pharma LLC announced today that 4 posters regarding psoriasis treatment SERNIVO® (betamethasone dipropionate) Spray, 0.05% will be presented at the Fall Clinical Dermatology Conference® in Las Vegas, NV, October...More \232aPromius Pharma LLC announced today that 4 posters regarding psoriasis treatment SERNIVO® (betamethasone dipropionate) Spray, 0.05% will be presented at the Fall Clinical Dermatology Conference® in Las Vegas, NV, October...More \232aGlobal Veterinary Anti-infectives Market, 2017-2025 - Growing Concerns About Animal Meat Quality
Global Veterinary Anti-infectives Market, 2017-2025 - Growing Concerns About Animal Meat Quality
The "Global Veterinary Anti-infectives Market Analysis & Trends - Industry Forecast to 2025" report has been added to Research and Markets' offering. The Global Veterinary Anti-infectives Market is poised to grow...More \232aThe "Global Veterinary Anti-infectives Market Analysis & Trends - Industry Forecast to 2025" report has been added to Research and Markets' offering. The Global Veterinary Anti-infectives Market is poised to grow...More \232aCalifornia dietary supplement maker, Custompax prohibited from manufacturing
California dietary supplement maker, Custompax prohibited from manufacturing
A California dietary supplement manufacturer recently was ordered by a federal court to stop selling its products until the company comes into compliance with the U.S. Food and Drug Administration's dietary supplement...More \232aA California dietary supplement manufacturer recently was ordered by a federal court to stop selling its products until the company comes into compliance with the U.S. Food and Drug Administration's dietary supplement...More \232aBiologic and Medical Imaging Reagents 2017: Applications & Industry Structure
Biologic and Medical Imaging Reagents 2017: Applications & Industry Structure
The "Biologic and Medical Imaging Reagents: Global Markets" report has been added to Research and Markets' offering. The scope of the study includes the biological imaging reagents that are already commercialized or...More \232aThe "Biologic and Medical Imaging Reagents: Global Markets" report has been added to Research and Markets' offering. The scope of the study includes the biological imaging reagents that are already commercialized or...More \232aGlobal Genomics Market - Forecast to Reach $23.8 Billion by 2022
Global Genomics Market - Forecast to Reach $23.8 Billion by 2022
The "Genomics Market - Forecast to 2022" report has been added to Research and Markets' offering. The global Genomics market is expected to reach USD 23.88 Billion by 2022 from USD 14.71 Billion in 2017, at a CAGR of...More \232aThe "Genomics Market - Forecast to 2022" report has been added to Research and Markets' offering. The global Genomics market is expected to reach USD 23.88 Billion by 2022 from USD 14.71 Billion in 2017, at a CAGR of...More \232aGlobal Cryogenic Vials Market: Growth Propped by Investments in Drug Development - Transparency Market Research
Global Cryogenic Vials Market: Growth Propped by Investments in Drug Development - Transparency Market Research
A study by Transparency Market Research predicts the global cryogenic vial market to rise at a tepid pace. By clocking a CAGR of 3.9% during the period between 2017 and 2027, the market is expected to attain a value of...More \232aA study by Transparency Market Research predicts the global cryogenic vial market to rise at a tepid pace. By clocking a CAGR of 3.9% during the period between 2017 and 2027, the market is expected to attain a value of...More \232aDaily Technical Summary Reports on Medical Equipment Stocks -- Invacare, ResMed, Stryker, and Zimmer Biomet
Daily Technical Summary Reports on Medical Equipment Stocks -- Invacare, ResMed, Stryker, and Zimmer Biomet
If you want a Stock Review on IVC, RMD, SYK, or ZBH then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com scans four equities to see how they...More \232aIf you want a Stock Review on IVC, RMD, SYK, or ZBH then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com scans four equities to see how they...More \232aUMA Health Fills Important Gap in Trump's Insurance Rule Cut
UMA Health Fills Important Gap in Trump's Insurance Rule Cut
UMA Health (UMA) announced today its insurance-free, affordable health care marketplace is the ideal way for patients to shop for doctors while taking advantage of President Trump's changes to the Affordable Care Act...More \232aUMA Health (UMA) announced today its insurance-free, affordable health care marketplace is the ideal way for patients to shop for doctors while taking advantage of President Trump's changes to the Affordable Care Act...More \232aBioArctic's Patent for its Product Candidate Antibody BAN0805, for Parkinson's Disease, is Now Granted in Europe
BioArctic's Patent for its Product Candidate Antibody BAN0805, for Parkinson's Disease, is Now Granted in Europe
BioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European patent (EP2539366) to BioArctic AB and the patent will be published on November 08, 2017. ...More \232aBioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European patent (EP2539366) to BioArctic AB and the patent will be published on November 08, 2017. ...More \232aDr. Bastian Dehmel Appointed CMO of OxThera
Dr. Bastian Dehmel Appointed CMO of OxThera
OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr. Bastian Dehmel as their new Chief Medical Officer. OxThera is developing a novel treatment, Oxabact, for...More \232aOxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr. Bastian Dehmel as their new Chief Medical Officer. OxThera is developing a novel treatment, Oxabact, for...More \232aMultiparameter Patient Monitoring - Medical Devices Pipeline Assessment, 2017
Multiparameter Patient Monitoring - Medical Devices Pipeline Assessment, 2017
Multiparameter Patient Monitoring - Medical Devices Pipeline Assessment, 2017 Summary Read the full report: https://www.reportlinker.com/p04415891 GlobalData's Medical Devices sector report, "Multiparameter Patient...More \232aMultiparameter Patient Monitoring - Medical Devices Pipeline Assessment, 2017 Summary Read the full report: https://www.reportlinker.com/p04415891 GlobalData's Medical Devices sector report, "Multiparameter Patient...More \232aGlobal $41 Bn Respiratory Drugs Market to 2023 - Leading Players are GSK, AstraZeneca and Boehringer Ingelheim
Global $41 Bn Respiratory Drugs Market to 2023 - Leading Players are GSK, AstraZeneca and Boehringer Ingelheim
The "Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth...More \232aThe "Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth...More \232aGlobal Cancer Immunotherapies Markets, 2017 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
Global Cancer Immunotherapies Markets, 2017 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, October 12, 2017 /PRNewswire/ -- The "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" dru...More \232aInformation contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, October 12, 2017 /PRNewswire/ -- The "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" dru...More \232aGlobal Teleradiology Market Expected to Reach $7,345 Million by 2023 - Allied Market Research
Global Teleradiology Market Expected to Reach $7,345 Million by 2023 - Allied Market Research
According to a new report published by Allied Market Research, titled, "Teleradiology Market by Imaging Techniques, Technology, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global...More \232aAccording to a new report published by Allied Market Research, titled, "Teleradiology Market by Imaging Techniques, Technology, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global...More \232aStand Up To Cancer Catalyst® Launches 10 Clinical Trial Projects Combining Cancer Treatments from 9 Different Pharmaceutical Companies to Explore Innovative Approaches and Find New Indications for Blockbuster Drugs from Major Companies to Improve Patient
Stand Up To Cancer Catalyst® Launches 10 Clinical Trial Projects Combining Cancer Treatments from 9 Different Pharmaceutical Companies to Explore Innovative Approaches and Find New Indications for Blockbuster Drugs from Major Companies to Improve Patient
Stand Up To Cancer (SU2C) has awarded 10 SU2C Catalyst® clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate borders on clinical trials -- with correlated...More \232aStand Up To Cancer (SU2C) has awarded 10 SU2C Catalyst® clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate borders on clinical trials -- with correlated...More \232aGlobal Idiopathic Pulmonary Fibrosis Market Expected to Reach $3,569 Million by 2023 - Allied Market Research
Global Idiopathic Pulmonary Fibrosis Market Expected to Reach $3,569 Million by 2023 - Allied Market Research
According to a new report published by Allied Market Research, titled, "Idiopathic Pulmonary Fibrosis Market by Type of Drug: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global idiopathic pulmonary...More \232aAccording to a new report published by Allied Market Research, titled, "Idiopathic Pulmonary Fibrosis Market by Type of Drug: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global idiopathic pulmonary...More \232aRealSelf Announces Partnership to Support Training and Mentoring of Female Surgeons in Africa
RealSelf Announces Partnership to Support Training and Mentoring of Female Surgeons in Africa
RealSelf, the most trusted online destination to get informed about elective cosmetic treatments and find the right provider, announced a partnership with Mission: Restore to support the next generation of female surgeons...More \232aRealSelf, the most trusted online destination to get informed about elective cosmetic treatments and find the right provider, announced a partnership with Mission: Restore to support the next generation of female surgeons...More \232aInfinity Announces IPI-549 Late-Breaking Presentation at SITC Annual Meeting
Infinity Announces IPI-549 Late-Breaking Presentation at SITC Annual Meeting
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that an abstract describing new data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits...More \232aInfinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that an abstract describing new data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits...More \232aGlobal Forensic Technologies Report 2017 - New and Growing Markets to 2022 with Focus on the US
Global Forensic Technologies Report 2017 - New and Growing Markets to 2022 with Focus on the US
The "Forensic Technologies: New and Growing Markets" report has been added to Research and Markets' offering. The Major U.S. Forensic Products and Services Market is Expected to Grow to Nearly $13.3 Billion in 2017...More \232aThe "Forensic Technologies: New and Growing Markets" report has been added to Research and Markets' offering. The Major U.S. Forensic Products and Services Market is Expected to Grow to Nearly $13.3 Billion in 2017...More \232aFDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verzenio™ (abemaciclib), a cyclin-dependent...More \232aEli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verzenio™ (abemaciclib), a cyclin-dependent...More \232aResearchers and Advocates Honored for Pioneering Efforts to End Lupus
Researchers and Advocates Honored for Pioneering Efforts to End Lupus
Aurinia Pharmaceuticals and Dr. Richard and Michelle Glickman; the Schwab family and Piper Jaffray; and Stephen, Lisa and Shea Evans were recognized for their trailblazing work to put an end to the devastating impact lupus...More \232aAurinia Pharmaceuticals and Dr. Richard and Michelle Glickman; the Schwab family and Piper Jaffray; and Stephen, Lisa and Shea Evans were recognized for their trailblazing work to put an end to the devastating impact lupus...More \232aArdelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Ardelyx, Inc. (NASDAQ: ARDX) today reported positive results from T3MPO-2, its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation (IBS-C). The study hit statistical significance for the...More \232aArdelyx, Inc. (NASDAQ: ARDX) today reported positive results from T3MPO-2, its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation (IBS-C). The study hit statistical significance for the...More \232aAbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017
AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017
AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced that it will present new data evaluating MAVYRET™ (glecaprevir/pibrentasvir), its once-daily, ribavirin-free treatment...More \232aAbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced that it will present new data evaluating MAVYRET™ (glecaprevir/pibrentasvir), its once-daily, ribavirin-free treatment...More \232aCancer Biomarkers Market Research Report 2017-2022
Cancer Biomarkers Market Research Report 2017-2022
The "Cancer Biomarkers Market by Type, Cancer Type, Profiling Technology, Application - Global Forecast to 2022" report has been added to Research and Markets' offering. The global cancer biomarkers market is...More \232aThe "Cancer Biomarkers Market by Type, Cancer Type, Profiling Technology, Application - Global Forecast to 2022" report has been added to Research and Markets' offering. The global cancer biomarkers market is...More \232aStudy finds significant overlap in the drugs covered by Canadian public drug plans
Study finds significant overlap in the drugs covered by Canadian public drug plans
OTTAWA, Oct.11, 2017 /CNW/ - The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System research initiative, today published Alignment Among Public Formularies...More \232aOTTAWA, Oct.11, 2017 /CNW/ - The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System research initiative, today published Alignment Among Public Formularies...More \232aGlobal Towards Natural Antimicrobials for Wound Dressings Report 2017 Featuring 3M, Covidien, & Smyth & Nephew
Global Towards Natural Antimicrobials for Wound Dressings Report 2017 Featuring 3M, Covidien, & Smyth & Nephew
The "Towards Natural Antimicrobials for Wound Dressings" report has been added to Research and Markets' offering. This report will discuss the use of antibacterial wound dressings and currently used technical...More \232aThe "Towards Natural Antimicrobials for Wound Dressings" report has been added to Research and Markets' offering. This report will discuss the use of antibacterial wound dressings and currently used technical...More \232aGlobal Bispecific Antibody Therapeutics Market, 2017-2030 - Overall Pipeline Comprises of 200+ Molecules
Global Bispecific Antibody Therapeutics Market, 2017-2030 - Overall Pipeline Comprises of 200+ Molecules
The "Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030" report has been added to Research and Markets' offering. The Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030' report...More \232aThe "Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030" report has been added to Research and Markets' offering. The Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030' report...More \232aAmgen Chairman and CEO Robert A. Bradway Elected PhRMA Board Chairman-Elect
Amgen Chairman and CEO Robert A. Bradway Elected PhRMA Board Chairman-Elect
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) elected new officers to its board of directors. Robert A. Bradway, chairman and CEO, Amgen was elected chairman-elect effective immediately. Olivier...More \232aToday, the Pharmaceutical Research and Manufacturers of America (PhRMA) elected new officers to its board of directors. Robert A. Bradway, chairman and CEO, Amgen was elected chairman-elect effective immediately. Olivier...More \232aGlobal Holter Monitoring Systems Strategic Business Report 2017 - Key Players are GE Healthcare, Mortara Instrument/Cardiac Science, Philips Healthcare, Schiller & Spacelabs
Global Holter Monitoring Systems Strategic Business Report 2017 - Key Players are GE Healthcare, Mortara Instrument/Cardiac Science, Philips Healthcare, Schiller & Spacelabs
The "Holter Monitoring Systems - Global Strategic Business Report" report has been added to Research and Markets' offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe,...More \232aThe "Holter Monitoring Systems - Global Strategic Business Report" report has been added to Research and Markets' offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe,...More \232aUS Market Report for Foot and Ankle Devices 2017
US Market Report for Foot and Ankle Devices 2017
The "US Market Report for Foot and Ankle Devices 2017 - MedCore" report has been added to Research and Markets' offering. Foot and ankle medical devices are used to treat a variety of indications, including hallux...More \232aThe "US Market Report for Foot and Ankle Devices 2017 - MedCore" report has been added to Research and Markets' offering. Foot and ankle medical devices are used to treat a variety of indications, including hallux...More \232aUS Hand and Wrist Devices Market Report 2017
US Hand and Wrist Devices Market Report 2017
The "US Market Report for Hand and Wrist Devices 2017 - MedCore" report has been added to Research and Markets' offering. The wrist is the articulation of the two forearm bones, the ulna and the radius, with the...More \232aThe "US Market Report for Hand and Wrist Devices 2017 - MedCore" report has been added to Research and Markets' offering. The wrist is the articulation of the two forearm bones, the ulna and the radius, with the...More \232aUnited States Small Bone and Joint Orthopedic Devices Product Portfolio Report 2017
United States Small Bone and Joint Orthopedic Devices Product Portfolio Report 2017
The "US Product Portfolio for Small Bone and Joint Orthopedic Devices 2017 - MedFolio" report has been added to Research and Markets' offering. The small joint market includes medical devices for restoring and...More \232aThe "US Product Portfolio for Small Bone and Joint Orthopedic Devices 2017 - MedFolio" report has been added to Research and Markets' offering. The small joint market includes medical devices for restoring and...More \232aGlobal Intraoral Scanners Market Expected to Reach $557 Million by 2023 - Allied Market Research
Global Intraoral Scanners Market Expected to Reach $557 Million by 2023 - Allied Market Research
According to a new report published by Allied Market Research, titled, "Intraoral Scanners Market by Brand and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global intraoral scanners...More \232aAccording to a new report published by Allied Market Research, titled, "Intraoral Scanners Market by Brand and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global intraoral scanners...More \232aGlobal Diabetes Therapeutics Market Expected to Reach $186,842 Million by 2023 - Allied Market Research
Global Diabetes Therapeutics Market Expected to Reach $186,842 Million by 2023 - Allied Market Research
According to a new report published by Allied Market Research, titled, "Diabetes Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global diabetes therapeutics market was valued at...More \232aAccording to a new report published by Allied Market Research, titled, "Diabetes Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global diabetes therapeutics market was valued at...More \232aIn Singapore, OneOme and Tucker Medical Partner to Improve Preventive Care and Oncology Treatments
In Singapore, OneOme and Tucker Medical Partner to Improve Preventive Care and Oncology Treatments
In Singapore, OneOme and Tucker Medical are working together to help improve preventive care and oncology treatments. OneOme is a leader in pharmacogenomic testing and Tucker Medical is a multi-specialty practice offering...More \232aIn Singapore, OneOme and Tucker Medical are working together to help improve preventive care and oncology treatments. OneOme is a leader in pharmacogenomic testing and Tucker Medical is a multi-specialty practice offering...More \232aBranched Chain Amino Acids - A Global Market Overview 2017-2022: Demand from Sports Nutrition and Animal Feed Sector Drives the Demand for BCAAs to Reach 36K Metric Tons by 2022
Branched Chain Amino Acids - A Global Market Overview 2017-2022: Demand from Sports Nutrition and Animal Feed Sector Drives the Demand for BCAAs to Reach 36K Metric Tons by 2022
The "Branched Chain Amino Acids - A Global Market Overview" report has been added to Research and Markets' offering. Demand from Sports Nutrition and Animal Feed Sector Drives the Demand for BCAAs to Reach 36K Metric...More \232aThe "Branched Chain Amino Acids - A Global Market Overview" report has been added to Research and Markets' offering. Demand from Sports Nutrition and Animal Feed Sector Drives the Demand for BCAAs to Reach 36K Metric...More \232aGlobal $114 Bn Antibody Drugs Technologies and Markets, 2017-2022
Global $114 Bn Antibody Drugs Technologies and Markets, 2017-2022
The "Antibody Drugs: Technologies and Global Markets" report has been added to Research and Markets' offering. The Global Market for Antibody Drugs Should Reach $114.6 Billion by 2022 Increasing from $84.5 Billion in...More \232aThe "Antibody Drugs: Technologies and Global Markets" report has been added to Research and Markets' offering. The Global Market for Antibody Drugs Should Reach $114.6 Billion by 2022 Increasing from $84.5 Billion in...More \232aVanrx Pharmasystems white paper describes "Multiplex" strategy to achieve flexibility and scale in biopharmaceutical manufacturing
Vanrx Pharmasystems white paper describes "Multiplex" strategy to achieve flexibility and scale in biopharmaceutical manufacturing
VANCOUVER, Oct. 11, 2017 /PRNewswire/ - Vanrx Pharmasystems has released Manufacturing Injectables in the Multiplex, a white paper that describes a strategy to achieve flexibility and scale in biopharmaceutical manufacturing.More \232aVANCOUVER, Oct. 11, 2017 /PRNewswire/ - Vanrx Pharmasystems has released Manufacturing Injectables in the Multiplex, a white paper that describes a strategy to achieve flexibility and scale in biopharmaceutical manufacturing.More \232aInternationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Today, Peter Moffat, Executive Producer of HBO's The Night Of, unveiled Understand AD: A Day in the Life in partnership with Sanofi, Regeneron Pharmaceuticals, and the National Eczema Association. Coinciding with...More \232aToday, Peter Moffat, Executive Producer of HBO's The Night Of, unveiled Understand AD: A Day in the Life in partnership with Sanofi, Regeneron Pharmaceuticals, and the National Eczema Association. Coinciding with...More \232aMabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers
MabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced the...More \232aMabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced the...More \232aProMIS Neurosciences Provides Third Quarter Update for 2017
ProMIS Neurosciences Provides Third Quarter Update for 2017
Updated corporate overview available on ProMIS websiteMore \232aUpdated corporate overview available on ProMIS websiteMore \232aBC Bud. BC Tweed. Canopy Growth establishes joint venture to convert 1.3 million square feet of existing greenhouse in British Columbia
BC Bud. BC Tweed. Canopy Growth establishes joint venture to convert 1.3 million square feet of existing greenhouse in British Columbia
JOINT VENTURE INCLUDES OPTION FOR ADDITIONAL 1.7 MILLION SQ. FT. GREENHOUSEMore \232aJOINT VENTURE INCLUDES OPTION FOR ADDITIONAL 1.7 MILLION SQ. FT. GREENHOUSEMore \232aConcordia International Corp. Announces New Communication With CMA
Concordia International Corp. Announces New Communication With CMA
OAKVILLE, ON, Oct. 11, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European...More \232aOAKVILLE, ON, Oct. 11, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European...More \232aInhaled Drug Delivery Annual Conference (London, United Kingdom - November 13th-14th, 2017)
Inhaled Drug Delivery Annual Conference (London, United Kingdom - November 13th-14th, 2017)
The "Inhaled Drug Delivery" conference has been added to Research and Markets' offering. Industry case studies, regulatory updates, latest therapies and technology innovations This annual conference includes...More \232aThe "Inhaled Drug Delivery" conference has been added to Research and Markets' offering. Industry case studies, regulatory updates, latest therapies and technology innovations This annual conference includes...More \232a
PR Newswire IndexMore>>
Entertainment News Releases via PRNewswire
Entertainment
Entertainment News Releases via PRNewswire
Travel
Travel News Releases via PRNewswire
Political Campaigns
Political Campaigns News Releases via PRNewswire
Medicine & Pharmaceuticals
Medicine & Pharmaceuticals News Releases via PRNewswire
Film & Motion Picture News Releases via PRNewswire
Film & Motion Picture
Film & Motion Picture News Releases via PRNewswire
Economic News and Analysis
Economic News Releases via PRNewswire
Computer Software
Computer Software News Releases via PRNewswire
Computer Networks
Computer Networks News Releases via PRNewswire
Computer Hardware
Computer Hardware News Releases via PRNewswire
Biotech News Releases via PRNewswire
Biotechnology
Biotechnology News Releases via PRNewswire
